Regeneron Pharmaceuticals, Inc. — Q2 2014 Form 10-Q Summary
Business context and reporting period
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines. Its marketed products were EYLEA, ZALTRAP, and ARCALYST, with 16 clinical programs in development. This unaudited Form 10-Q covers the three and six months ended June 30, 2014, compared with the corresponding 2013 periods.
Financial performance and liquidity
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Total revenue | $665.7 million | $457.6 million | $1,291.4 million | $897.3 million |
| Operating income | $222.4 million | $158.1 million | $408.3 million | $311.2 million |
| Operating margin | 33.4% | 34.5% | 31.6% | 34.7% |
| Net income | $92.7 million | $87.4 million | $158.2 million | $186.3 million |
| Diluted EPS | $0.82 | $0.79 | $1.40 | $1.69 |
| Net margin | 13.9% | 19.1% | 12.2% | 20.8% |
| Net cash from operations | Not separately provided | Not separately provided | $381.3 million | $214.4 million |
- Q2 revenue increased 45.4% year over year; first-half revenue increased 43.9%.
- Net product sales were $418.0 million in Q2 and $780.4 million in the first half. U.S. EYLEA sales were $414.8 million and $773.8 million, respectively. ARCALYST sales declined to $3.2 million in Q2 and $6.6 million in the first half.
- Collaboration revenue rose to $239.9 million in Q2 and $495.7 million in the first half, driven by higher Sanofi reimbursements and Bayer HealthCare EYLEA-related profit share and milestones.
- Research and development expense increased 57.1% to $294.5 million in Q2 and 58.2% to $581.9 million in the first half, primarily reflecting higher clinical, manufacturing, staffing, and collaborator cost-sharing activities.
- Effective tax rates increased to 54.3% in Q2 and 58.2% in the first half, versus 40.8% and 35.7%, respectively, in the prior-year periods. Drivers included expiration of the federal research tax credit, foreign losses, and New York tax legislation.
- At June 30, 2014, cash and cash equivalents were $600.1 million and marketable securities were $767.6 million, or $1.37 billion combined. Total assets were $3.46 billion and stockholders’ equity was $2.37 billion.
- Net cash used in investing activities was $354.4 million, including $135.7 million of capital expenditures and net purchases of marketable securities. Management expected approximately $220 million to $290 million of additional capital expenditures during the remainder of 2014.
- Convertible senior notes had $338.9 million of aggregate principal outstanding after $61.1 million was converted during Q2. The company paid $143.0 million to reduce associated warrants and recognized a $10.8 million debt-extinguishment loss.
Material changes versus the prior comparable period
- EYLEA U.S. sales increased 25.8% in Q2 and 20.2% in the first half, primarily from higher volume. EYLEA sales outside the United States reported by Bayer HealthCare increased to $246.8 million in Q2 and $464.9 million in the first half.
- Bayer HealthCare collaboration revenue increased to $97.3 million in Q2 and $222.6 million in the first half, including $15.0 million of Q2 sales milestones and $45.0 million of first-half sales milestones.
- Sanofi collaboration revenue increased to $142.6 million in Q2 and $273.1 million in the first half. The 2013 comparable periods included $20.0 million of upfront payments to Sanofi for acquired antibody rights, making the comparison less recurring.
- Despite higher operating income, first-half net income declined 15.1% because of substantially higher income taxes and increased operating and other expenses. Q2 net income increased 6.1%.
- Operating leverage weakened as operating expenses grew faster than revenue, particularly due to R&D expansion, commercialization activities, facilities, and non-cash stock compensation. Non-cash compensation was $70.5 million in Q2 and $151.9 million in the first half.
- The company entered a research collaboration with Avalanche Biotechnologies, making $8.0 million of upfront and research prepayments and purchasing $5.0 million of preferred stock. A further $10.0 million purchase of Avalanche common stock was triggered by its July 2014 IPO, subject to closing conditions.
- In July 2014, the FDA approved EYLEA for diabetic macular edema. The filing also reported positive late-stage results for alirocumab and dupilumab and continued regulatory activity for additional EYLEA indications.
Guidance, outlook, commentary, risks, and unusual items
- Management stated that existing capital resources, anticipated EYLEA sales, and collaborator reimbursements should meet projected operating needs for the foreseeable future, while warning that expenses are expected to continue increasing.
- Near-term priorities included continued Phase 3 development of sarilumab and alirocumab, planned U.S. and European regulatory filings for alirocumab, Phase 3 advancement of dupilumab in atopic dermatitis, and regulatory decisions for EYLEA in branch retinal vein occlusion and additional international indications.
- Management identified substantial dependence on EYLEA: U.S. EYLEA sales represented 60% of total revenue in the first half of 2014. Key risks include competition, payer coverage and reimbursement, regulatory compliance, manufacturing capacity, adverse events, and customer concentration.
- Besse Medical, a subsidiary of AmerisourceBergen, accounted for 76% of gross product revenue in the first half of 2014, creating significant distributor concentration.
- Sanofi and Bayer HealthCare collaborations are important sources of funding and revenue. The company had contingent reimbursement obligations to Sanofi for ZALTRAP and Bayer HealthCare for EYLEA, which are expected to reduce future collaboration profits.
- Fasinumab and nesvacumab remained subject to FDA partial clinical holds. Development of REGN2009 was discontinued, and Sanofi elected not to continue co-development of enoticumab.
- Patent infringement proceedings involving the company’s ’287 and ’018 patents were at an early stage, and the company could not predict the outcome or estimate any potential gain.
- The company purchased, together with Sanofi, an FDA priority review voucher for $67.5 million in July 2014, with the purchase price shared equally. The voucher was intended for the planned alirocumab application.
- The company was evaluating the impact and transition method for the new revenue-recognition standard effective for periods beginning after December 15, 2016.
Most important facts for investors to verify
- Whether EYLEA volume growth, pricing, reimbursement, and international expansion can offset concentration and competitive risks.
- The recurring versus milestone-driven composition of Bayer and Sanofi collaboration revenue.
- The effect of higher R&D spending, collaborator cost-sharing, stock compensation, and elevated tax rates on sustainable earnings and margins.
- Progress, safety, regulatory status, and filing timing for alirocumab, dupilumab, sarilumab, and additional EYLEA indications.
- Execution and funding requirements for the planned $220 million to $290 million of second-half 2014 capital expenditures and manufacturing expansion.
- Terms and potential financial impact of contingent reimbursement obligations, Genentech royalties, convertible notes, warrants, and pending intellectual-property litigation.
- Reliance on Sanofi, Bayer HealthCare, Besse Medical, third-party manufacturers, and other collaborators or distributors.